--- title: "Vertex Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors" type: "News" locale: "en" url: "https://longbridge.com/en/news/296534046.md" description: "Vertex Pharmaceuticals (VRTX) shares fell 2.14% to $540.26 on Thursday, underperforming competitors like AbbVie and Krystal Biotech while Arcturus Therapeutics rose. The decline ended a three-day winning streak and left the stock 2.43% below its 52-week high. Trading volume was below the 50-day average. This occurred during a broader market downturn where the S&P 500 and Dow Jones also declined." datetime: "2026-08-20T20:37:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296534046.md) - [en](https://longbridge.com/en/news/296534046.md) - [zh-HK](https://longbridge.com/zh-HK/news/296534046.md) generator: "portal-rs" --- # Vertex Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Vertex Pharmaceuticals Inc. (VRTX) slid 2.14% to $540.26 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.87% to 7,641.16 and Dow Jones Industrial Average falling 1.32% to 52,759.21. The stock's fall snapped a three-day winning streak. Vertex Pharmaceuticals Inc. closed 2.43% below its 52-week high of $553.69, which the company achieved on August 19th. The stock underperformed when compared to some of its competitors Thursday, as AbbVie Inc. (ABBV) fell 1.56% to $261.83, Krystal Biotech Inc. (KRYS) fell 1.84% to $337.02, and Arcturus Therapeutics Holdings Inc. (ARCT) rose 6.91% to $10.99. Trading volume (1.1 M) remained 555,889 below its 50-day average volume of 1.6 M. Data source: Dow Jones Market Data, FactSet. Data compiled August 20, 2026. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 08-20-26 1637ET ### Related Stocks - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) - [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md) - [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [KRYS.US](https://longbridge.com/en/quote/KRYS.US.md) - [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md) ## Related News & Research - [Are Wall Street Analysts Bullish on Vertex Stock?](https://longbridge.com/en/news/296449653.md) - [The Bull Case For Vertex (VRTX) Could Change Following Upgraded 2026 Guidance And Pipeline Momentum - Learn Why](https://longbridge.com/en/news/296583461.md) - [TFR Capital LLC. Takes Position in Vertex Pharmaceuticals Incorporated $VRTX](https://longbridge.com/en/news/296021261.md) - [$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/295956299.md) - [Crinetics supplements proxy disclosures for Vertex USD 85-per-share buyout after shareholder suits](https://longbridge.com/en/news/296395094.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**